AstraZeneca PLC AstraZeneca prices a $2.25bn bond offering (4227R)
March 01 2023 - 2:00AM
UK Regulatory
TIDMAZN
RNS Number : 4227R
AstraZeneca PLC
01 March 2023
1 March 2023 07:00 GMT
AstraZeneca prices a $2.25bn bond offering
AstraZeneca PLC ("AstraZeneca") announces that its wholly owned
subsidiary AstraZeneca Finance LLC, priced a three tranche global
bond offering totalling $2.25bn on 28 February 2023. The offering
is expected to close on 3 March 2023, subject to customary closing
conditions. The transaction, which is a global offering registered
with the US Securities and Exchange Commission ("SEC"), consists of
the following three tranches:
Notes issued by AstraZeneca Finance LLC and fully and
unconditionally guaranteed by AstraZeneca
-- $1.1bn of fixed rate notes with a coupon of 4.875%, maturing 3 March 2028;
-- $650m of fixed rate notes with a coupon of 4.900%, maturing 3 March 2030; and
-- $500m of fixed rate notes with a coupon of 4.875%, maturing 3 March 2033.
AstraZeneca expects to use the net proceeds of the offering for
general corporate purposes, which may include the refinancing of
existing indebtedness.
BofA Securities, Inc., HSBC Securities (USA) Inc., Mizuho
Securities USA LLC and Santander US Capital Markets LLC acted as
joint book-running managers on the transaction. In addition, and in
line with our commitment to Inclusion & Diversity, the
women-owned firms R. Seelaus & Co., LLC and Tigress Financial
Partners LLC also acted as underwriters on the transaction.
The notes will be issued under AstraZeneca's effective shelf
registration statement on Form F-3, which AstraZeneca and
AstraZeneca Finance LLC filed with the SEC on 24 May 2021. The
offering is being made solely by means of the prospectus contained
within that shelf registration statement, along with a prospectus
supplement forming part of the effective registration statement,
which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting BofA
Securities, Inc., NC1-004-03-43 200 North College Street, 3rd
Floor, Charlotte, NC, 28255-0001, Attn: Prospectus Department by
telephone at 1-800-294-1322 or by emailing
dg.prospectus_requests@bofa.com ; HSBC Securities (USA) Inc., 452
Fifth Avenue, New York, NY 10018, by telephone at 1-866-811-8049;
Mizuho Securities USA LLC, 1271 Avenue of the Americas, New York,
NY 10020, by telephone at 1- 866-271-7403; or Santander US Capital
Markets LLC by telephone at 1-855-403-3636. Readers may also
download these documents for free by visiting the Electronic Data
Gathering, Analysis, and Retrieval (EDGAR) system on the SEC
website at www.sec.gov .
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact AstraZeneca's financial
guidance for 2023.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide.
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IODDZGZZZRFGFZZ
(END) Dow Jones Newswires
March 01, 2023 02:00 ET (07:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024